Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback